In addition, both GLP1‐based therapy and SGLT2 inhibitors may have a more pronounced effect on the pathophysiological mechanisms involved in MASLD/MASH like the positive effects on body weight and the anti‐inflammatory effects. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.